Hubei Biocause Heilen Pharmaceutical Co. Ltd. (SHE:301211) — Market Cap & Net Worth
Market Cap & Net Worth: Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (SHE:301211) has a market capitalization of $642.86 Million (CN¥4.39 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10854 globally and #2928 in its home market, demonstrating a 3.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s stock price CN¥10.52 by its total outstanding shares 417600000 (417.60 Million). See 301211 capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap History: 2021 to 2026
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.81 Billion to $662.41 Million (-19.95% CAGR).
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.65x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 1.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.39x
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap is 21.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.81 Billion | $540.62 Million | $121.65 Million | 3.35x | 14.88x |
| 2022 | $1.69 Billion | $514.91 Million | $125.79 Million | 3.28x | 13.43x |
| 2023 | $1.29 Billion | $663.03 Million | $176.12 Million | 1.95x | 7.33x |
| 2024 | $1.30 Billion | $445.86 Million | $91.55 Million | 2.91x | 14.19x |
| 2025 | $746.74 Million | $453.31 Million | $34.91 Million | 1.65x | 21.39x |
Competitor Companies of 301211 by Market Capitalization
Companies near Hubei Biocause Heilen Pharmaceutical Co. Ltd. in the global market cap rankings as of August 5, 2026.
Key companies related to Hubei Biocause Heilen Pharmaceutical Co. Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s market cap moved from $1.81 Billion to $ 662.41 Million, with a yearly change of -19.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥662.41 Million | -11.29% |
| 2025 | CN¥746.74 Million | -42.52% |
| 2024 | CN¥1.30 Billion | +0.57% |
| 2023 | CN¥1.29 Billion | -23.55% |
| 2022 | CN¥1.69 Billion | -6.62% |
| 2021 | CN¥1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Hubei Biocause Heilen Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $642.86 Million USD |
| MoneyControl | $642.86 Million USD |
| MarketWatch | $642.86 Million USD |
| marketcap.company | $642.86 Million USD |
| Reuters | $642.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more